# Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

> **NCT02780011** · PHASE1 · WITHDRAWN · sponsor: **Eric Bernicker, MD**

## Conditions studied

- CD30-positive Lymphoma
- CD30-positive Solid Tumor

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Alsertib

## Key facts

- **NCT ID:** NCT02780011
- **Lead sponsor:** Eric Bernicker, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-12
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of funding
- **Last updated:** 2018-07-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02780011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02780011, "Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02780011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*